TLR4-IN-C34
博飞美科提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
PA92273
PERFEMIKER
40592-88-9
C17H27NO9
389.40
*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!
| 产品名称： |
TLR4-IN-C34,98% |
| 中文别名： |
异丙基2-乙酰氨基-2-脱氧-3,4,6-三-O-乙酰基α-D-吡喃葡糖苷;异丙基 2-(乙酰氨基)-2-脱氧-alpha-D-吡喃葡萄糖苷 3,4,6-三乙酸酯 |
| 英文名称： |
TLR4-IN-C34 |
| 英文别名： |
C34;Isopropyl 2-(acetylamino)-2-deoxy á-D-glucopyranoside 3,4,6-triacetate;2-Acetamidopyranoside;Isopropyl 2-(acetylamino)-2-deoxy α-D-glucopyranoside 3,4,6-triacetate;(2R,3S,4R,5R,6S)-5-Acetamido-2-(acetoxymethyl)-6-isopropoxytetrahydro-2H-pyran-3,4-diyl diacetate;C17H27NO9;BICL4343;SYN5106;AOB4594;1-Methylethyl 2-(acetylamino)-2-deoxy-?-D-glucopyranoside 3,4,6-triacetate;Isopropyl 2-(acetylamino)-2-deoxy aacute-D-glucopyranoside 3,4,6-triacetate;Tlr4-IN-C34;TLR4-IN-C34 |
| 品牌： |
PERFEMIKER |
| CAS号： |
40592-88-9 |
| 分子式： |
C17H27NO9 |
| 分子量： |
389.40 |
| 纯度： |
98% |
| 详细描述： |
博飞美科的TLR4-IN-C34,98%为抑制剂,产品稳定,定制速度快,极大地方便了广大科研客户的使用需求。产品包装为5mg。查询关键词:抑制剂，40592-88-9，TLR4-IN-C34,98%，TLR4-IN-C34，博飞美科，Perfemiker，上海，厂家直销。 |
沪公网安备31011402010658号 
C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d(C(%5bH%5d)(%5bH%5d)%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%5d1(%5bH%5d)C(C2C(%3dC3C(%3dC(C(%5bH%5d)(%5bH%5d)%5bH%5d)C(%3dC(%5bH%5d)C3%3dC(%5bH%5d)C%3d2C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(C(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bC%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)O%5bH%5d)O%5bH%5d)
C%3d2)F)%3dO)%5bC%40H%5d1C1C%3dNC%3dCC%3d1)%3dO)(F)F)
%3dO)C(COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)
O)O)C%2fC%3dC%5cCCC(%3dO)OC)